



Ion channels as targets to treat cystic fibrosis lung disease

S. Lorraine Martin, Vinciane Saint-Criq, Tzyh-Chang Hwang, László Csanády

► To cite this version:

S. Lorraine Martin, Vinciane Saint-Criq, Tzyh-Chang Hwang, László Csanády. Ion channels as targets to treat cystic fibrosis lung disease. *Journal of Cystic Fibrosis*, 2018, 17 (2), pp.S22-S27. 10.1016/j.jcf.2017.10.006 . hal-02385564

HAL Id: hal-02385564

<https://hal.science/hal-02385564>

Submitted on 28 Nov 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Invited Review

Ion channels as targets to treat cystic fibrosis lung disease

S. Lorraine Martin ^{a,*}, Vinciane Saint-Criq ^b, Tzyh-Chang Hwang ^c, László Csanády ^d^a School of Pharmacy, Queen's University Belfast, Northern Ireland, UK^b Institute for Cell and Molecular Biosciences, The Medical School, Newcastle University, Newcastle upon Tyne, UK^c Dalton Cardiovascular Research Center, University of Missouri, Columbia, MO 65211, USA^d Department of Medical Biochemistry, Semmelweis University, Budapest 1094, Hungary

Received 16 August 2017; revised 9 October 2017; accepted 9 October 2017

Available online 6 November 2017

Abstract

Lung health relies on effective mucociliary clearance and innate immune defence mechanisms. In cystic fibrosis (CF), an imbalance in ion transport due to an absence of chloride ion secretion, caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) and a concomitant sodium hyperabsorption, caused by dysregulation of the epithelial sodium channel (ENaC), results in mucus stasis which predisposes the lungs to cycles of chronic infection and inflammation leading to lung function decline.

An increased understanding of CFTR structure and function has provided opportunity for the development of a number of novel modulators targeting mutant CFTR however, it is important to also consider other ion channels and transporters present in the airways as putative targets for drug development. In this review, we discuss recent advances in CFTR biology which will contribute to further drug discovery in the field. We also examine developments to inhibit the epithelial sodium channel (ENaC) and potentially activate alternative chloride channels and transporters as a multi-tracked strategy to hydrate CF airways and restore normal mucociliary clearance mechanisms in a manner independent of CFTR mutation. © 2017 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Keywords: Cystic fibrosis; CFTR; ENaC; Ion channel; Proteases; Airways hydration; Ion transporter; Anion exchanger

1. Introduction

Cystic fibrosis (CF) is the most common life-limiting, hereditary condition which affects Caucasian populations with morbidity and premature mortality associated predominantly with chronic lung disease [1]. It is caused by mutations in the

CFTR (cystic fibrosis transmembrane conductance regulator) gene which encodes an ATP-dependent, apical membrane-associated chloride ion channel which plays a pivotal role in the regulation of ion secretion and absorption across epithelial cells. There are currently over 2000 known CFTR mutations, although fewer than 20 mutations occur at a frequency of >0.1% and only 5 at a frequency >1% [2]. These mutations are grouped into 6 classes depending on the degree to which the CFTR mutation affects CFTR quantity, transport to or function at the cell surface, however as our understanding of CFTR structure and function increases, further sub- or re-classification may assist current aspirations for a fully personalized medicines approach to this disease [2].

The CF phenotype, which in addition to the lungs, affects the pancreas, liver, kidneys and intestines is however not just the result of abnormal CFTR-mediated Cl[−] secretion. Indeed, a loss of CFTR function, can also affect a number of other key

Abbreviations: ABC, ATP Binding Cassette; AE, anion exchanger; ASL, airways surface liquid; ATP, adenosine triphosphate; CAP, channel activating protease; CaCC, calcium activated chloride channel; CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator; ΔF508, CFTR mutation encoding a deletion of phenylalanine at position 508; ENaC, epithelial sodium channel; HAT, human airways trypsin-like protease; NBD, nucleotide binding domain; NHE, Na⁺/H⁺ exchanger; NKCC1, Na-K-Cl cotransporter; PKA, protein kinase A; siRNA, small-interfering RNA; UTP, uridine triphosphate

* Corresponding author at: School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast BT44 9HB, Northern Ireland, UK.

E-mail address: l.martin@qub.ac.uk (S.L. Martin).

ion channels, transporters and pumps which contribute to lung health by working together to ensure effective mucociliary clearance and innate immune defence mechanisms through the optimization of cell surface hydration, charge and pH [3]. In particular, the build-up of, and inability to clear, mucus in CF airways is due to an observed reduction in airway surface liquid (ASL) volume which is fundamentally a result of sodium hyperabsorption caused by dysregulation of the epithelial sodium channel (ENaC) in the cells lining the airways [4].

In this Review, we summarise the key areas covered in Symposium 6: *Cell Physiology and Ion Transport*, and highlight in particular recent developments in our understanding of CFTR structure and function as well as novel strategies to target ENaC. Other ion channels, such as the TMEM16A chloride channel and the calcium-activated potassium channel $KCa3.1$, and ion transporters are also presented as alternative pathways to restore surface hydration and pH in CF airways by increasing chloride and/or bicarbonate secretion. These approaches, summarized in Fig. 1, offer very attractive targets for

pharmacological intervention, and importantly could complement current drug therapies focused on the correction of CFTR mutations which together could result in the development of a broader arsenal of disease-modifying treatments for CF.

2. Recent developments in our understanding of CFTR structure and function

The CFTR chloride channel is a member of the family of ATP Binding Cassette (ABC) proteins, and is built from two homologous halves each containing a transmembrane domain (TMD) followed by a cytosolic nucleotide binding domain (NBD). In CFTR these two halves are linked by the unique cytosolic regulatory (R) domain [5] which inhibits channel activity unless phosphorylated by cyclic AMP-dependent protein kinase (PKA) [6,7]. Unlike in other ABC proteins which are mostly active transporters, in CFTR the TMDs form a transmembrane anion-selective pore. Nevertheless, the molecular motions that drive uphill substrate translocation in ABC proteins




Fig. 1. Alternative channels and transporters for the regulation of ASL height (A) and ASL pH (B), in CF. A. Modulation of Cl^- and Na^+ transport involves increasing anion and fluid secretion (by activating the blue channels and transporters) and/or decreasing Na^+ and fluid absorption (by inhibiting the red channels and transporters). Anion secretion can be increased by activating Ca^{2+} -activated Cl^- channels (CaCC), such as TMEM16A, or Cl^- channels, such as SLC26A9 on the apical membrane. K^+ secretion on the apical surface can also regulate ASL volume. On the basolateral membrane, a Na-K-Cl cotransporter (NKCC1) is the limiting factor for Cl^- entry into the cells and K^+ recycling through basolateral K^+ channels, such as KCNQ1, provides the driving force for transcellular Cl^- secretion. Inhibition of ENaC reduces Na^+ hyperabsorption and fluid absorption which increases ASL volume. Inhibition of pendrin, an anion exchanger (AE) has also been shown to increase airways hydration. B. Modulation of HCO_3^- and H^+ transport involves increasing apical HCO_3^- secretion or basolateral H^+ secretion (through blue channels and transporters) and/or decreasing apical H^+ secretion and basolateral bicarbonate (HCO_3^-) secretion (through red channels and transporters). Theoretically, activation of any apical HCO_3^- transporter could increase ASL pH, such as CaCC or pendrin. Inhibiting apical Na^+/H^+ exchangers (NHE; such as NHE3/SLC9A3, a modifier gene associated with severity of CF lung disease), H^+ channels, H^+/K^+ -ATPase or V-ATPase could also increase ASL pH. In the cytoplasm, the carbonic anhydrase (CA) is involved in the CO_2/HCO_3^- buffering system and could contribute to the regulation of ASL pH by increasing intracellular HCO_3^- concentration. In the basolateral membrane, activating NHE could prevent apical H^+ secretion and inhibiting anion exchange could sustain intracellular HCO_3^- concentration required for its apical secretion.

but pore opening and closing (gating) in CFTR are highly conserved. The CFTR channel pore opens upon dimerization of its two NBDs, and closes upon disruption of this dimer following ATP hydrolysis [8]. In the tight NBD dimer canonical motifs of both NBDs form two non-equivalent composite ATP binding sites. Composite site 2, formed by Walker motifs of NBD2 and the signature sequence motif of NBD1, is catalytically active, and hydrolyses ATP in each gating cycle. In contrast, composite site 1, formed by Walker motifs of NBD1 and the signature sequence motif of NBD2, is catalytically inactive, and keeps ATP bound throughout several gating cycles [9,10]. Thermodynamic studies suggest that the pore opening conformational transition is initiated by tightening of the site-2 NBD interface, and that movements in this composite site are already completed in the opening transition state [11].

In contrast, little is known about the role and precise timing of molecular motions in composite site 1. Although profound effects on channel gating kinetics of site-1 perturbations suggest gating-associated motions also take place in this site [12,13], the physical extent of such motions is debated [14–16]. Analysis of energetic profiles of channels gating in the absence and presence of ATP indicate that ATP bound at the dimer interface stabilizes the open state relative to the opening transition state, suggesting that this interface undergoes rearrangements between the transition state and the open state [17]. Insofar as motions at the site-2 interface are likely completed in the transition state, one possible explanation is that these further rearrangements occur at the site-1 interface. Recent thermodynamic studies presented at the Symposium indeed support such an interpretation, and suggest delayed movement in site 1 relative to site 2 during pore opening.

As described above, the major “driving force” for opening CFTR’s gate is attributed to ATP binding and subsequent NBD dimerization at composite site 2 [8,18], but how ATP binding at composite site 1 contributes to this process is unclear. Although it has been shown that mutating the conserved Walker A lysine (K464) at this site decreases the apparent affinity of ATP for CFTR gating by >10-fold [18–20], on the contrary, reported that mutations such as K464A or W401G, which presumably weaken ATP binding at composite site 1, do not affect the sensitivity of CFTR to ATP. These two latter reports, however, show a shortening of the open time by these mutations. If closing of CFTR’s gate is driven by disruption of the NBD dimer, normally controlled by ATP hydrolysis at composite site 2 [21], this result suggests that the structure/function status of site 1 may affect the hydrolysis rate at composite site 2, and/or the stability of the pre-hydrolytic NBD dimer.

A potential role of composite site 1 in CFTR gating was revealed by a study that used the high-affinity ATP analog N⁶-phenylethyl ATP (P-ATP) as an alternative ligand [16]. This study led to a proposition that a complete gating cycle is coupled to ATP hydrolysis at composite site 2 while composite site 1 remains occupied. The data presented at the Symposium extend this idea and suggest that gating becomes much less effective when composite site 1 is empty, probably because an unoccupied site 1 enables a wider separation of the two NBDs and hence hinders NBD dimerization at composite site 2.

Indeed, a pathogenic mutation G1349D that presumably prevents association of NBDs at composite site 1 drastically dampens ATP-dependent gating [22]. As both composite ATP-binding sites are located at the NBD interface, it seems not surprising that a functional interaction between them should take place. Deciphering the precise nature of this interaction awaits further studies.

This continued expansion of our knowledge of CFTR structure and function will undoubtedly contribute to ongoing drug development in the field, recent advances in which have been extensively reviewed elsewhere [2,23].

3. Targeting ENaC

Within the airways, the epithelial sodium channel (ENaC) has been found to be solely responsible for the absorption of Na⁺ and, in CF, its dysregulation is now known to directly contribute to mucus stasis and impaired mucus clearance [24].

ENaC is composed of three structurally related subunits (α , β and γ), which include two membrane-spanning domains connected by a large extracellular loop [25,26]. Although ENaC can be regulated by multiple pathways e.g. cAMP [24] and SPLUNC-1 [26], it is activated by the proteolytic processing of its subunits leading to an increase in channel conductance [24,27]. The importance of proteases in ENaC activation in CF is further supported by evidence indicating that wild-type CFTR physically associates with ENaC, impedes proteolysis and suppresses channel opening, whereas Δ F508 CFTR fails to protect ENaC from proteolytic cleavage and stimulation [28].

Channel activating proteases (CAPs) predominantly belong to the trypsin-like family of serine proteases as studies investigating ENaC processing and activation have, to date, determined multiple Arg and Lys cleavage sites on α and γ subunits: e.g., γ Lys¹⁹⁴ (plasmin) [29]; α Arg²⁰⁵, α Arg²³¹ and γ Arg¹⁴³ (furin); γ Lys¹⁸⁶ (prostasin; CAP-1) [30] and γ Arg¹³⁸ (CAP-2) [31]. Neutrophil elastase, which is associated widely with chronic airways disease, can also cleave ENaC γ although a pre-processing step by furin is thought to be required for complete elastase-induced activation of ENaC [27]. Although, the specific CAPs responsible for ENaC activation in CF airways have yet to be defined, both host and bacterial enzymes are implicated, the impact of their activities further exacerbated by the protease-antiprotease imbalance associated with disease progression. A broad spectrum approach to the inhibition of trypsin-like serine proteases in CF has however, been validated using both macromolecular protease inhibitors (aprotinin) and the low molecular weight inhibitor Camostat, which were found to attenuate ENaC and improve mucociliary clearance [32,33].

Recent work, presented at the Symposium, describes the development of a novel rationally-designed compound (QUB-TL1) whose inhibition of excessive apical CAP activity is restricted to the extracellular surface of airway epithelial cells [34]. The broad spectrum inhibition of putative CAPs, to include human airways trypsin-like protease (HAT), prostasin, matriptase and furin resulted in diminished ENaC-mediated Na⁺ absorption in CF primary human airway epithelial cells (hAECs) and the internalization of a

prominent pool of cleaved (active) ENaC γ from the cell surface. Furthermore, diminished amiloride-sensitive ENaC activity correlated with an increase in ASL height and restored normal mucociliary clearance. A further novel trypsin-like inhibitor, NAP-858 was also reported for the first time. QUB-TL1 and NAP-858 dampen CAPs-ENaC signaling which improves hydration status and mucociliary clearance in CF airway epithelial cell cultures and may provide a mechanism to delay or prevent the development of CF lung disease in a manner independent of CF transmembrane conductance regulator mutation.

A number of other approaches targeting ENaC function as a treatment for CF are at various stages of development [35]. The *in vitro* and *in vivo* efficacy of SPX-101, peptide mimetic of SPLUNC1 has recently been reported [36]. SPX-101 has been shown to bind to ENaC and to promote internalization of α , β and γ subunits in both CF and healthy primary hAECs, which similarly to QUB-TL1 caused a significant decrease in amiloride-sensitive current. *In vivo* studies found that once daily dosing with SPX-101 had the ability to increase survival of β ENaC transgenic mice to >90% and increased mucus transport in both the β ENaC mouse and sheep models of CF.

Genomic approaches to ENaC inhibition has also been extensively considered and to date has involved the design of siRNA to α ENaC and delivery to airway cells using nanoparticle formulations [37,38]. Delivery of siRNA using both liquid nanoparticle formulations [37] and a novel self-assembly nanocomplex formulation [38] were able to silence expression of the α ENaC subunit gene and warrant further evaluation as potential novel inhaled therapeutics for CF.

4. Alternative ion channels and transporters in CF

Beyond CFTR and ENaC, other ion channels and transporters are being investigated as potential alternative pathways to restore airway surface hydration (Fig. 1A) and pH (Fig. 1B) by increasing chloride and/or bicarbonate secretion.

Airway epithelia respond to Ca^{2+} agonists, such as ATP and UTP, by a large increase in Cl^- secretion, and therefore possess a Ca^{2+} -activated Cl^- conductance. In 2008, 3 different research groups have identified TMEM16A, also named Anoctamin-1, as a calcium dependent chloride channel expressed in airway epithelial cells [39–41]. Moreover, it has been shown that, besides Cl^- , this channel is permeable to HCO_3^- [42]. Theoretically, activating this channel could therefore increase ASL hydration and pH. However, it has been reported that TMEM16A expression is increased in response to pro-inflammatory stimuli, associated with goblet cell metaplasia [43] and increased in airways of asthmatic patients [44]. Nevertheless, small molecules activating or inhibiting this channel are being developed as its role in CF pathophysiology is further investigated [45,46].

The SLC26 family encodes anion exchangers and channels, two of which are of particular interest in the search for alternative pathways in CF lung pathophysiology. SLC26A4, also known as pendrin, is an electroneutral $\text{Cl}^-/\text{HCO}_3^-$ exchanger expressed in epithelial cells of many organs, including the airways, and plays an important role in the lung innate immune defence by transporting thiocyanate [47]. In Calu-3 cells, it is

mainly responsible for HCO_3^- secretion [48] and could therefore be targeted in order to increase ASL pH in CF. However, a recent study reported that pendrin inhibition increased ASL hydration [49]. Thus establishing the therapeutic potential of the modulation of pendrin activity may prove to be difficult. SLC26A9, unlike the other members of the SLC26 family, is a Cl^- channel involved in resting and cAMP-regulated Cl^- secretion. Multiple reports provide strong evidence for this channel as a modifier gene in CF and other lung diseases [50] and Single Nucleotide Polymorphisms in this gene have been associated with severity of lung pathology in individuals with CF and asthma. However, regulation of this channel has yet to be fully understood and to date, no specific modulator of its activity has been identified. Therefore, although SLC26A9 is a very strong candidate for an alternative Cl^- pathway in CF, much progress is still required before it can be fully considered as a therapeutic target.

Basolateral K^+ channels maintain the membrane potential and provide the driving force for Cl^- secretion. Moreover, it was shown that activating a Ca^{2+} regulated K^+ channel (KCNN4) with 1-EBIO increased Na^+ absorption across CF airways epithelial cells [51]. Therefore, it appears that modulating K^+ channel activity could modulate ASL hydration and might restore an efficient mucociliary clearance in CF cells.

Finally, recent studies have demonstrated the importance of ASL pH in airway hydration, bacterial killing, antimicrobial peptide activity and mucus rheology. Thus adjusting H^+ and HCO_3^- secretion could, theoretically, improve the CF lung physiology. Modulating Na^+/H^+ exchangers, H^+ or HCO_3^- conducting channels and transporters could also increase ASL pH, reversing different hallmarks of the CF lungs, regardless of the CFTR mutation. Several reports showed the prominent role of ATP12A, an H^+/K^+ -ATPase, in the acidic ASL found in CF airways [52,53] and inhibiting this pump could therefore be beneficial for CF airways.

5. Conclusion

It is clear that cell physiology and ion transport in CF is complex and requires an understanding not just of the disease-causing CFTR gene, and the structure and function of the CFTR protein but of the number of other ion channels and transporters that contribute to the electrophysiological balance within the airways, many of which are impacted by the loss of functional CFTR. When the CFTR gene and its association to CF was discovered in 1989 by Dr. Lap-Chee Tsui and colleagues it was not expected that gene therapy and ultimate cure for CF would remain a holy grail [5]. Increases in life expectancy over the last number of decades have instead been due to improvements in disease management and treatment [1]. It is however hoped that recent progress in the development of CFTR modulators (potentiators, correctors, amplifiers, read-through agents and stabilisers) in various combinations will provide further opportunity to improve both quality of life and the life expectancy of those living with CF, although it will not be without its challenges [23].

An alternative, potentially complementary and highly attractive strategy is the targeting of other ion channels which offers an opportunity to develop ion transport modulation therapies irrespective of an individual's CFTR genotype [2,50]. A number of pharmacological and genomic approaches to inhibit ENaC are at various stages of development [34,36–38]. The identification of alternative chloride channels and potassium channels involved in the maintenance of ion balance and pH in the airways also offer new targets for drug development [39,49]. A multi-track approach to enable Cl^- secretion by a reconstitution of the defective CFTR or through the activation of alternative Cl^- channels and by blocking ENaC to prevent Na^+ hyperabsorption will therefore be critical to ensure future improvements in the health of individuals with CF.

Acknowledgements

We acknowledge the support of the organising committee of the European Cystic Fibrosis Basic Science conference 2017 and the contributions that were also made by Drs Paolo Scudieri (Telethon Institute of Genetics and Medicine) and Génesis Vega (Centro de Estudios Científicos, Valdivia, Chile) to Symposium 6 (Cell Physiology and Ion Transport) of the conference. SLM's work has received financial support from the CF Trust, UK (PJ552 and PJ559), Invest Northern Ireland (POC600) and the Medical Research Council (MC_PC_141113); VSC is currently funded by a Strategic Research Centre grant (INOVCF/SRC003) from the CF Trust UK; TCH by research grants from the NIH (R01DK55835) and Cystic Fibrosis Foundation (Hwang11P0) and LC by a Research Grant from the Cystic Fibrosis Foundation (CSANAD17G0).

Conflicts of interest

The authors declare there is no conflict of interests between them and regarding the publication of this paper.

Author contributions

All authors drafted the review manuscript or revised it critically for important intellectual content. All authors approved the final version of the review manuscript.

References

- [1] Elborn JS. Cystic fibrosis. *Lancet* 2016;388:2519–31.
- [2] De Boeck K, Amaral MD. Progress in therapies for cystic fibrosis. *Lancet Respir Med* 2016;4:662–74.
- [3] Knowles MR, Boucher RC. Mucus clearance as a primary innate defense mechanism for mammalian airways. *J Clin Invest* 2002;109:571–7.
- [4] Knowles MR, Stutts MJ, Spock A, Fischer N, Gatzky JT, Boucher RC. Abnormal ion permeation through cystic fibrosis respiratory epithelium. *Science* 1983;221:1067–70.
- [5] Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. *Science* 1989;245:1066–73.
- [6] Anderson MP, Berger HA, Rich DP, Gregory RJ, Smith AE, Welsh MJ. Nucleoside triphosphates are required to open the CFTR chloride channel. *Cell* 1991;67:775–84.
- [7] Liu F, Zhang Z, Csanady L, Gadsby DC, Chen J. Molecular structure of the human CFTR ion channel. *Cell* 2017;169:85–95 e8.
- [8] Vergani P, Lockless SW, Nairn AC, Gadsby DC. CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains. *Nature* 2005;433:876–80.
- [9] Basso C, Vergani P, Nairn AC, Gadsby DC. Prolonged nonhydrolytic interaction of nucleotide with CFTR's NH2-terminal nucleotide binding domain and its role in channel gating. *J Gen Physiol* 2003;122:333–48.
- [10] Ramjeesingh M, Li C, Garami E, Huan LJ, Galley K, Wang Y, et al. Walker mutations reveal loose relationship between catalytic and channel-gating activities of purified CFTR (cystic fibrosis transmembrane conductance regulator). *Biochemistry* 1999;38:1463–8.
- [11] Sorum B, Czege D, Csanady L. Timing of CFTR pore opening and structure of its transition state. *Cell* 2015;163:724–33.
- [12] Csanady L, Mihalyi C, Szollosi A, Torocsik B, Vergani P. Conformational changes in the catalytically inactive nucleotide-binding site of CFTR. *J Gen Physiol* 2013;142:61–73.
- [13] Tsai MF, Jih KY, Shimizu H, Li M, Hwang TC. Optimization of the degenerated interfacial ATP binding site improves the function of disease-related mutant cystic fibrosis transmembrane conductance regulator (CFTR) channels. *J Biol Chem* 2010;285:37663–71.
- [14] Chaves LA, Gadsby DC. Cysteine accessibility probes timing and extent of NBD separation along the dimer interface in gating CFTR channels. *J Gen Physiol* 2015;145:261–83.
- [15] Szollosi A, Muallem DR, Csanady L, Vergani P. Mutant cycles at CFTR's non-canonical ATP-binding site support little interface separation during gating. *J Gen Physiol* 2011;137:549–62.
- [16] Tsai MF, Li M, Hwang TC. Stable ATP binding mediated by a partial NBD dimer of the CFTR chloride channel. *J Gen Physiol* 2010;135:399–414.
- [17] Mihalyi C, Torocsik B, Csanady L. Obligate coupling of CFTR pore opening to tight nucleotide-binding domain dimerization. *Elife* 2016;5.
- [18] Zhou Z, Wang X, Liu HY, Zou X, Li M, Hwang TC. The two ATP binding sites of cystic fibrosis transmembrane conductance regulator (CFTR) play distinct roles in gating kinetics and energetics. *J Gen Physiol* 2006;128:413–22.
- [19] Powe Jr AC, Al-Nakkash L, Li M, Hwang TC. Mutation of Walker-A lysine 464 in cystic fibrosis transmembrane conductance regulator reveals functional interaction between its nucleotide-binding domains. *J Physiol* 2002;539:333–46.
- [20] Vergani P, Nairn AC, Gadsby DC. On the mechanism of MgATP-dependent gating of CFTR Cl^- channels. *J Gen Physiol* 2003;121:17–36.
- [21] Gunderson KL, Kopito RR. Conformational states of CFTR associated with channel gating: the role ATP binding and hydrolysis. *Cell* 1995;82:231–9.
- [22] Bompadre SG, Sohma Y, Li M, Hwang TC. G551D and G1349D, two CF-associated mutations in the signature sequences of CFTR, exhibit distinct gating defects. *J Gen Physiol* 2007;129:285–98.
- [23] Fajac I, De Boeck K. New horizons for cystic fibrosis treatment. *Pharmacol Ther* 2017;170:205–11.
- [24] Gaillard EA, Kota P, Gentzsch M, Dokholyan NV, Stutts MJ, Tarran R. Regulation of the epithelial Na^+ channel and airway surface liquid volume by serine proteases. *Pflugers Arch* 2010;460:1–17.
- [25] Canessa CM, Schild L, Buell G, Thorens B, Gautschi I, Horisberger JD, et al. Amiloride-sensitive epithelial Na^+ channel is made of three homologous subunits. *Nature* 1994;367:463–7.
- [26] Garcia-Caballero A, Rasmussen JE, Gaillard E, Watson MJ, Olsen JC, Donaldson SH, et al. SPLUNC1 regulates airway surface liquid volume by protecting ENaC from proteolytic cleavage. *Proc Natl Acad Sci U S A* 2009;106:11412–7.
- [27] Myerburg MM, Harvey PR, Heidrich EM, Pilewski JM, Butterworth MB. Acute regulation of the epithelial sodium channel in airway epithelia by proteases and trafficking. *Am J Respir Cell Mol Biol* 2010;43:712–9.
- [28] Gentzsch M, Dang H, Dang Y, Garcia-Caballero A, Suchindran H, Boucher RC, et al. The cystic fibrosis transmembrane conductance regulator impedes proteolytic stimulation of the epithelial Na^+ channel. *J Biol Chem* 2010;285:32227–32.

- [29] Passero CJ, Mueller GM, Rondon-Berrios H, Tofovic SP, Hughey RP, Kleyman TR. Plasmin activates epithelial Na⁺ channels by cleaving the gamma subunit. *J Biol Chem* 2008;283:36586–91.
- [30] Hughey RP, Bruns JB, Kinlough CL, Harkleroad KL, Tong Q, Carattino MD, et al. Epithelial sodium channels are activated by furin-dependent proteolysis. *J Biol Chem* 2004;279:18111–4.
- [31] Garcia-Caballero A, Dang Y, He H, Stutts MJ. ENaC proteolytic regulation by channel-activating protease 2. *J Gen Physiol* 2008;132: 521–35.
- [32] Bridges RJ, Newton BB, Pilewski JM, Devor DC, Poll CT, Hall RL. Na⁺ transport in normal and CF human bronchial epithelial cells is inhibited by BAY 39-9437. *Am J Physiol Lung Cell Mol Physiol* 2001;281:L16–23.
- [33] Coote K, Atherton-Watson HC, Sugar R, Young A, MacKenzie-Beevor A, Gosling M, et al. Camostat attenuates airway epithelial sodium channel function in vivo through the inhibition of a channel-activating protease. *J Pharmacol Exp Ther* 2009;329:764–74.
- [34] Reihill JA, Walker B, Hamilton RA, Ferguson TE, Elborn JS, Stutts MJ, et al. Inhibition of protease-epithelial Sodium Channel signaling improves mucociliary function in cystic fibrosis airways. *Am J Respir Crit Care Med* 2016;194:701–10.
- [35] Smith NJ, Solovay CF. Epithelial Na⁺ channel inhibitors for the treatment of cystic fibrosis. *Pharm Pat Anal* 2017;6:179–88.
- [36] Scott DW, Walker MP, Sesma J, Wu B, Stuhlmiller TJ, Sabater JR, et al. SPX-101 is a novel ENaC-targeted therapeutic for cystic fibrosis that restores mucus transport. *Am J Respir Crit Care Med* 2017.
- [37] Clark KL, Hughes SA, Bulsara P, Coates J, Moores K, Parry J, et al. Pharmacological characterization of a novel ENaCalpha siRNA (GSK2225745) with potential for the treatment of cystic fibrosis. *Mol Ther Nucleic Acids* 2013; e65:2.
- [38] Manunta MD, Tagalakis AD, Attwood M, Aldossary AM, Barnes JL, Munye MM, et al. Delivery of ENaC siRNA to epithelial cells mediated by a targeted nanocomplex: a therapeutic strategy for cystic fibrosis. *Sci Rep* 2017;7:700.
- [39] Caputo A, Caci E, Ferrera L, Pedemonte N, Barsanti C, Sondo E, et al. TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity. *Science* 2008;322:590–4.
- [40] Schroeder BC, Cheng T, Jan YN, Jan LY. Expression cloning of TMEM16A as a calcium-activated chloride channel subunit. *Cell* 2008; 134:1019–29.
- [41] Yang YD, Cho H, Koo JY, Tak MH, Cho Y, Shim WS, et al. TMEM16A confers receptor-activated calcium-dependent chloride conductance. *Nature* 2008;455:1210–5.
- [42] Jung J, Nam JH, Park HW, Oh U, Yoon JH, Lee MG. Dynamic modulation of ANO1/TMEM16A HCO₃[−] permeability by Ca²⁺/calmodulin. *Proc Natl Acad Sci U S A* 2013;110:360–5.
- [43] Scudieri P, Caci E, Bruno S, Ferrera L, Schiavon M, Sondo E, et al. Association of TMEM16A chloride channel overexpression with airway goblet cell metaplasia. *J Physiol* 2012;590:6141–55.
- [44] Huang F, Zhang H, Wu M, Yang H, Kudo M, Peters CJ, et al. Calcium-activated chloride channel TMEM16A modulates mucin secretion and airway smooth muscle contraction. *Proc Natl Acad Sci U S A* 2012;109: 16354–9.
- [45] Liu Y, Zhang H, Huang D, Qi J, Xu J, Gao H, et al. Characterization of the effects of Cl[−] channel modulators on TMEM16A and bestrophin-1 Ca(2⁺) activated Cl[−] channels. *Pflugers Arch* 2015;467:1417–30.
- [46] Seo Y, Lee HK, Park J, Jeon DK, Jo S, Jo M, et al. Ani9, a novel potent small-molecule ANO1 inhibitor with negligible effect on ANO2. *PLoS One* 2016;11:e0155771.
- [47] Pedemonte N, Caci E, Sondo E, Caputo A, Rhoden K, Pfeiffer U, et al. Thiocyanate transport in resting and IL-4-stimulated human bronchial epithelial cells: role of pendrin and anion channels. *J Immunol* 2007;178: 5144–53.
- [48] Gamett JP, Hickman E, Burrows R, Hegyi P, Tiszlavicz L, Cuthbert AW, et al. Novel role for pendrin in orchestrating bicarbonate secretion in cystic fibrosis transmembrane conductance regulator (CFTR)-expressing airway serous cells. *J Biol Chem* 2011;286:41069–82.
- [49] Haggie PM, Phuan PW, Tan JA, Zlock L, Finkbeiner WE, Verkman AS. Inhibitors of pendrin anion exchange identified in a small molecule screen increase airway surface liquid volume in cystic fibrosis. *FASEB J* 2016; 30:2187–97.
- [50] Mall MA, Galiotta LJ. Targeting ion channels in cystic fibrosis. *J Cyst Fibros* 2015;14:561–70.
- [51] Devor DC, Bridges RJ, Pilewski JM. Pharmacological modulation of ion transport across wild-type and DeltaF508 CFTR-expressing human bronchial epithelia. *Am J Physiol Cell Physiol* 2000;279:C461–79.
- [52] Coakley RD, Grubb BR, Paradiso AM, Gatzky JT, Johnson LG, Kreda SM, et al. Abnormal surface liquid pH regulation by cultured cystic fibrosis bronchial epithelium. *Proc Natl Acad Sci U S A* 2003;100:16083–8.
- [53] Shah VS, Meyerholz DK, Tang XX, Reznikov L, Abou Alaiwa M, Ernst SE, et al. Airway acidification initiates host defense abnormalities in cystic fibrosis mice. *Science* 2016;351:503–7.